Table 1.
Characteristics of SSc patients
| Patient | Disease subset | Duration of disease, years | mRSS | Autoantibodies | Internal organ involvement | Therapy before/during (b/d) pregnancy | BMI, kg/m2 | Comorbidities and risk factors | Age at conception, years | Gestational week at delivery | Obstetric complications | Newborn weight, g | Placental characteristics (descriptive) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1a | lc-SSc | 3 | 2 | ACA | None | b and d: levothyroxine, ASA | 21.5 | Gestational hypothyroidism | 34 | 38 + 6 | PROM | 3170 | Dystrophic calcifications, mild acute chorioamnionitis |
| 2a | lc-SSc | 1 | 4 | ACA | Gastrointestinal |
b: prostanoids. d: MPD 4 mg |
23.8 | — | 38 | 36 |
HELLP, preterm birth |
2660 | Hypoxic hypervascularization, syncytial knots, decidual inflammation |
| 3a | dc-SSc | 12 | 13 | Anti-Scl70 | None |
b: bosentan, prostanoids. d: CCB, ASA |
28.1 | — | 31 | 40 | — | 3175 | Focal subchorial fibrin deposits |
| 4a | dc-SSc | 1 | 3 | Anti-Scl70 | None | b and d: ASA | 22.6 | — | 33 | 40 | Preeclampsia | 3690 | Mild acute chorioamnionitis, low grade chronic villitis, few dystrophic calcifications |
| 5 | dc-SSc | 1 | 2 | Anti-Scl70 | None | b and d: ASA | 23.1 | — | 29 | 36 + 4 | Preterm birth | 2800 | Dystrophic calcifications, mild acute chorioamnionitis, fibrin deposits |
| 6 | dc-SSc | 4 | 6 | Anti-Scl70 | None | b: prostanoids. d: levothyroxine, ASA | 26 | Hashimoto’s thyroiditis | 29 | 40 | — | 3140 | Rare avascular villi, perivillous and villous fibrin deposits, focal chronic villitis |
| 7 | dc-SSc | 2 | 2 | Anti-Scl70 | None |
b: CCB d: LMWH, ASA |
25.5 | — | 35 | 26 | Preterm birth, IUGR, HELLP | 511, SGA | Villous haemorrhage, areas of infarction, decidual arteriopathy, mural thrombi |
| 8 | dc-SSc | 7 | 12 | Anti-Scl70 | Gastrointestinal, cardiopulmonary |
b: CCB d: ASA |
27 | — | 34 | 30 + 6 | Preterm birth, neonatal death | 1428 | Chronic decidual inflammation, decidual arteriopathy |
a
Patient with both paraffin and frozen samples. ASA: acetylsalicylic acid 100 mg; CCB: calcium channel blockers; dc-SSc: diffuse cutaneous SSc; HELLP: haemolysis, elevated liver enzymes, low platelets; IUGR: intrauterine growth restriction; lc-SSc: limited cutaneous SSc; LMWH: low molecular weight heparin; MPD: metylprednisolone; mRSS: modified Rodnan skin score; PROM: premature rupture of membranes; SGA: small for gestational age.